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ABSTRACT
Objective: To compare the prevalence and type of human papillomavirus (HPV) infections in the
genital tract of human-immunodeficiency-virus- (HIV) seropositive and -seronegative women
matched for cytology and to examine prospectively the relationship of HPV DNA, colposcopic
findings and cervical squamous intraepithelial lesions (SIL) in these matched seropositive and
seronegative cohorts.
Methods: A matched prospective study of HIV-seropositive and -seronegative women undergo-
ing cytologic screening, colposcopy, and testing for HPV DNA and other infections at each visit.
Results: Twenty-three HIV-seropositive women were matched with 23 seronegative women by
cervical cytology reading, lifetime number of sexual partners, age, and follow-up length. Fourteen
pairs of these women had follow-up visits every 4 months, for 56 and 53 total visits in seropositive
and seronegative women, respectively. After matching, the groups had a similar overall prevalence
ofHPVDNA and ofHPV oncogenic (high risk) types at baseline. On follow up, HIV-seropositive
women were more likely than seronegative women to develop SIL (38% vs. 10%), less likely to have
negative cytology (34% vs. 60%, overall P 0.03), more visits with HPV DNA detected (68% vs.
40% P 0.04), and more visits with multiple HPV DNA types detected (18% vs. 0%, P 0.02).
Colposcopic lesions in the seropositive women were more likely to have sharp borders or mosaicism
or to be thick white (P 0.009).
Conclusions: After matching for baseline Papanicolaou smear readings, these data suggest that
over time seropositive women have more visits that yield abnormal cytology, more persistent HPV
DNA detection, and more colposcopic abnormalities than seronegative women. Infect. Dis. Obstet.
Gynecol. 7:158-164, 1999. (C) 1999 Wiley-Liss, Inc.
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everal studies have demonstrated an increased
prevalence of squamous intraepithelial lesions
(SIL) in human-immunodeficiency-virus- (HIV)
seropositive women.-s While the natural history of
SIL in HIV-seropositive women has not been well
defined, an association between increased preva-
lence of human papillomavirus (HPV) DNA and
HIV has been found in many studies,z,4-9. These
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studies show an association between HPV DNA
detection, HIV serostatus, and the presence or ab-
sence of SIL.
While multiple studies show an association be-
tween HPV DNA, SIL, and HIV seropositivity,
most studies have been cross-sectional. Few stud-
ies include matching HIV-seropositive with HIV-
seronegative women for factors that have been as-
sociated with HPV DNA, such as number of sexual
partners, age, and cervical SIL. In addition, though
published prospective data on $IL in HIV-sero-
positive women has demonstrated persistence of
SIL,1 prospective reports on SIL with concurrent
HPV DNA detection, comparisons of colposcopic
findings, and screening for other vaginal and cervi-
cal infections in seropositive women are limited.
The purpose of this study was to examine HPV
DNA detection among HIV-seropositive and -se-
ronegative women initially matched for cytologic
abnormality, age, and number of sexual partners,
and to determine prospectively if cytologic abnor-
malities or HPV DNA detection differed among
these matched women over time. In addition to
HPV, colposcopic abnormalities as well as other
cervical and vaginal infections were compared be-
tween the seropositive and seronegative women.
SUBJECTS AND METHODS
The HIV-seropositive study group consisted of 23
women referred for gynecologic care between Au-
gust 1992 and July 1994 to the Northwest Family
Center, a Seattle-King County Public Health De-
partment clinic established to provide medical care
to families affected by HIV. Follow up was pos-
sible for 14 of these women, for a total of 56 ex-
aminations over the 23-month study interval.
Twenty-three HIV-seronegative women attending
the Seattle-King County Sexually Transmitted
Diseases Clinic who were enrolled in a previously
described study of the etiology and natural history
of cervical dysplasia11 were matched with the se-
ropositive women for comparison. All seronegative
women were available for follow-up evaluation, but
to maintain matching, only follow-up visits on the
subjects matched with the 14 seropositive women
were recorded, for a total of 53 examinations over
24 months. Matching was done by cervical cytology
reading at baseline, lifetime number of sexual part-
ners, (___five sexual partners), and age (within 5
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years with the exception of one woman) because
these factors have been associated with detection
of HPV DNA. 1z-a7 Additionally, because develop-
ment or persistence of abnormal cervical cytology
was a study endpoint, length of follow-up was also
matched. After informed consent was obtained, as
approved by the University of Washington Institu-
tional Review Board, each study participant under-
went a standardized history and physical examina-
tion, including colposcopic examination of the
vulva, vagina, and cervix.
The women were initially evaluated and then
asked to return every 4 months for repeat evalua-
tion. Culture and wet-mount techniques have been
described in detail previously.8 At each visit, ex-
amination and specimen collection included the
following. The lateral vaginal wall was swabbed
with a cotton-tipped applicator and placed into 0.2
mL of physiologic saline solution in a test tube.
One drop of this saline wet mount was placed on a
slide to evaluate for motile trichomonads and clue
cells. A second drop was placed on a slide with a
drop of 10% potassium hydroxide to assess amine
odor and presence of hyphae. A Papanicolaou
smear was obtained using an ectocervical wooden
spatula and an endocervical brush. Each specimen
was placed into fixative immediately. Dacron en-
docervical swabs were used to sample for Neisseria
gonorrhoeae culture and herpes simplex virus cul-
ture and a cytobrush was used to sample for Chla-
mydia trachomatis culture. One Dacron swab from
the vulva and 2 Dacron swabs from the vaginal
sidewall were placed into a 1-mL specimen trans-
port medium (STM; Digene Diagnostics, Silver
Spring, MD) for vulvar/vaginal HPV DNA detec-
tion. Another Dacron swab was used to sample the
ectocervix and endocervical canal and placed into
STM for cervical HPV DNA detection.
After collection of the samples, 5% acetic acid
was applied to the cervix, and colposcopy of the
cervix was performed and recorded on the stan-
dardized form. The cervical colposcopic examina-
tions were recorded onto a circular grid represent-
ing the cervix that was divided into 18 sections.
Extent of cervical lesion(s) was determined colpo-
scopically by adding the number of sections in-
volved, with a maximum of 18. Colposcopic le-
sions(s) were characterized by color, punctation,
mosaicism, border (sharp vs. diffuse), and location
relative to the squamocolumnar junction. The col-
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poscopic exams were performed by single examin-
ers blinded to HPV DNA results in each popula-
tion (Investigator L.E. for the seropositive women
and investigator C.S. for the seronegative women).
At each visit of the seropositive women, blood was
drawn for lymphocyte subset determination.
If a Pap smear showed atypia or low-grade SIL
(LGSIL), the patient was monitored with repeat
Pap smears every 4 months but without cervical
biopsy. After one high-grade SIL (HGSIL) Pap
smear or after two consecutive LGSIL Pap smears,
cervical biopsy was performed. Histologically con-
firmed SIL was treated by cryotherapy or loop elec-
trosurgical excision procedure (LEEP). If treat-
ment occurred, the patient was no longer eligible
for study follow up.
Polymerase chain reaction (PCR) amplification
was performed using L1 consensus HPV primers,
following previously described procedures. 19 Prod-
ucts of PCR amplification were blotted onto filters
and allowed to hybridize with a generic HPV probe
and groups of type-specific oligonucleotide probes:
HPV 6 and 11 (low risk), HPV 31, 33, 35, and 39
(intermediate risk) and HPV 16, 18, or 45 (high
risk). The PCR reaction mixtures also contained
13-globin primers PC04 and GH20 that were used
to prime the synthesis of a fragment of the ,human
13-globin gene. Amplified samples lacking the
13-globin fragment were considered to have insuf-
ficient numbers of eukaryotic cells present for HPV
types and were termed unsatisfactory. T-cell sub-
sets were done by flow cytometry using CD4 cul-
ture cytostat CD3/T4 antibodies. Statistical analy-
ses appropriate for comparisons of matched data
were performed. For dichotomous factors, McNe-
mar tests for matched pairs were used, while Wil-
coxon signed rank tests were used to evaluate as-
sociations among continuous factors. Follow-up
visits were analyzed using Kruskal-Wallis test for
association.
RESULTS
Of the 23 HIV-seropositive women, the mean CD4
count was 0.406 thou per mL (range 0-1.132).
Fourteen had contracted HIV via heterosexual con-
tact and nine via intravenous drug use. Table
compares the baseline characteristics in the HIV-
seropositive and -seronegative populations. The
mean age in the seropositive vs. seronegative
women was 31.7 vs. 30.4 years (P 0.2), and me-
TABLE I. Baseline characteristics of
HIV-seropositive and HIV-seronegative populations
matched for age, number of lifetime sexual partners,
and cervical cytology result
HIV+ HIV-
n 23 n 23
Characteristic (%) (%) P value
Age (mean) 31.7 30.4 0.2
Nonwhite race 9 (39) 2 (9) 0.008
Age of first intercourse 16.0 16.9 0.2
Lifetime partners (median) 15 13 0.5
Currently smoking 14 (6 I) (48) 0.4
Barrier contraception 12 (52) 8 (35) 0.3
Extent of lesion (mean) 4.7 4.2 0.6
Prior C. trachomatis/N, gonorrhoeae 9 (39) 10 (43) 0.7
Current cervical/vaginal infections
C. trachomatis/N, gonorrhoeae 1(04) 0 0.3
Yeast 5 (22) (04) 0.
Bacterial vaginosis 4 (17) 3 (I 3) 0.7
Herpes simplex virus 0 (04) 0.3
T. vaginalis 0 2 (09) 0.2
Papanicolaou smear
Negative 6 (26) 6 (26)
ASCUS 8 (35) 8 (35)
LGSIL 8 (35) 8 (35)
HGSIL I(04) I(04) 1.0
HPV DNA types
Low risk (6, I) 3 (I 3) 2 (9) 0.7
Intermediate risk
(31,33,35, or 39) 3 (I 3) 7 (30) 0.3
High risk (I 6,18, or 45) 4 (I 7) 5 (22) 0.7
Any HPV DNA 17 (74) 15 (65) 0.4
Multiple HPV types 5 (22) 4 (17) 0.7
aMcNemar’s test for matched pairs for dichotomous factors and Wil-
coxon signed rank test for continuous factors.
bColposcopically determined, cervical lesion extent recorded on a grid
with a maximum involvement of 18 sections.
CDiagnosis by culture.
dDiagnosis by wet mount.
eASCUS atypical squamous cells of undetermined significance.
flncludes low, intermediate, high or non-typed HPV DNA, HPV types
not exclusive.
dian number of lifetime sexual partners was 15 vs.
13 (P 0.5) in these two groups, reflecting the
baseline matching for these factors. Comparing
these matched women, no difference was found in
factors that have been associated with HPV DNA
detection, such as current smoking or age at first
intercourse. The seropositive women were more
likely to be of nonwhite race than the seronegative
women (39% versus 9%, P 0.008). Among those
with colposcopically detected lesions, the extent of
lesions seen by colposcopy was no different be-
.tween the matched HIV-seropositive and -seroneg-
ative women (mean of 4.7/18 sections versus 4.2/18
sections, P 0.6).
A past history of N. gonorrhoeae or C. trachomatis
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TABLE 2. Colposcopic features of cervical lesions seen initially and in follow up in matched HIV-seropositive
and -seronegative women
HIV+ HIV-
51 total visits 52 total visits
Features (%) (%) P value
Extent of lesion(s) (mean) 4.3 4.2 0.4
Number of lesions (mean) 1.6 1.2 0.07
Cervical lesions
Location
On junction 35/49 (71) 31 (60) 0.6
Remote from junction 19/49 (39) (2 I) 0.3
Mosaicism 38/49 (78) 22 (42) 0.01
Sharp borders 28 (55) 8 (15) 0.003
Thick white color 9 (18) 2 (04) 0.06
Mosaic, sharp, or white 44 (86) 25 (48) 0.009
aWilcoxon signed rank test.
bColposcopically determined cervical lesion extent recorded on grid with a maximum involvement of 18 sections.
was reported in a high proportion of both groups:
39% versus 43% in the seropositive v.s: seronega-
tire women (P 0.7). Current infection with C.
trachomatis, N. gonorrhoeae, herpes simplex virus, or
bacterial vaginosis was similar in both groups. Wet-
mount findings of yeast were more common in the
HIV-seropositive women than the seronegative
women (22% vs. 4%, P 0.1), whereas tricho-
monads were seen more frequently in the HIV-
seronegative women (9% vs. 0, P--0.2), though
neither reached statistical significance.
In both the HIV-seropositive and -seronegative
women studied, 8 of 23 (35%) had atypia on the
initial Pap smear and 8 of 23 (35%) had LGSIL,
reflecting matching for baseline cytologic reading.
After this baseline cytologic matching, HPV DNA
detection was similar in the seropositive and sero-
negative women, with a high overall prevalence in
both groups (78% and 69%, P 0.5) and similar
distributions of low-risk, intermediate-risk, high-
risk, and multiple HPV types.
Colposcopic examination results are presented
in Table 2. The mean extent of cervical lesions
seen per visit was 4.3 and 4.2 sections in the sero-
positive and seronegative women, respectively.
The mean number of cervical lesions seen on col-
poscopic exam was also similar in both groups. (1.6
and 1.2, respectively). Most of the cervical lesions
were on the squamocolumnar junction in each
group (71% and 60%, respectively). Mosaicism of
lesion(s) was seen in 78% of visits of the seroposi-
tive women vs. 42% of visits of the seronegative
women (P 0.01). Sharp borders were more com-
mon in the seropositive group (55% vs. 15%, P
0.003), as were thick white lesions (18% vs. 4%, P
0.06). Combining lesion abnormalities, 44 of 51
(80%) visits by seropositive women resulted in col-
poscopically detected mosaicism, sharp borders, or
thick white lesions versus 25 (48%) of 52 visits in
seronegative women (P 0.009).
Follow-up results are presented in Table 3. The
HIV-seropositive and -seronegative women had 32
and 30 follow-up visits for analysis, respectively.
Despite initial matching by Pap smear, cytologic
disparities developed between the two groups dur-
ing follow up. A negative Pap smear was found in
18 of the 30 follow-up visits (60%) by HIV-
seronegative women compared with 11 of the 32
visits (34%) by seropositive women, while SIL was
seen on 12 of the 32 follow-up smears (38%) in the
seropositive women vs. 3 of the 30 follow-up
smears (10%) in the seronegative women (overall,
P 0.03). Additionally, two of these SIL lesions
were HGSIL proven by biopsy in seropositive
women, and these women were treated. None of
the seronegative women developed HGSIL on fol-
low up or required treatment.
Additionally, despite similar prevalences of
HPV DNA detected on initial examination in these
matched women, on follow up, differences
emerged. Of the 28 follow-up visits during which
HPV DNA data was available for the seropositive
women, 19 of 28 (68%) revealed HPV DNA vs. 12
of 30 (40%) of the follow-up visits by seronegative
women (P 0.04). Multiple HPV DNA types were
also detected at the follow-up visits of the seropos-
itive but not the seronegative women (18% vs. 0, P
0.02). Low-, intermediate-, and high-risk HPV
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TABLE 3. Characteristics on follow-up visits of matched HIV-seropositive and HIV-seronegative women
HIV+ HIV-
32 total visits 30 total visits
(%) P value
Papanicolaou smear
Negative (34) 18 (60)
ASCUS 9 (28) 9 (30)
Any SIL 12 (38) 3 (I 0)
HPV DNA types
Low risk (6 or I) 4/28 (14) 0
Intermediate risk (31, 33, 35, or 39) 4/28 (14) 2 (7)
High risk (I 6, 18, or 45) 6/28 (21) 4 (I 3)
Any HPV DNA 19/28 (68) 12 (40)







aOverall P for difference between HIV+ and HIV- women by KruskaI-Wallis test for association.
bWilcoxon signed rank test.
Clncludes low, intermediate, high or non-typed HPV DNA; HPV types not exclusive.
DNA types were detected during 14%, 14%, and
21% of follow-up visits by seropositive women, re-
spectively, compared with 0, 7%, and 13% of fol-
low-up visits by seronegative women. Cervical/
vaginal infections with C. trachomatis, N. gonor-
rhoeae, yeast, bacterial vaginosis, herpes simplex
virus, or Trichomonas vaginalis were not different
between the two groups at follow up (data not
shown).
DISCUSSION
This study was designed to evaluate HPV DNA
presence in HIV-seropositive and -seronegative
women matched by cervical cytology, number of
lifetime sexual partners, and age, and to then pro-
spectively monitor and evaluate cytologic abnor-
malities, colposcopic findings, and HPV DNA de-
tection in these matched pairs ofwomen. The 78%
baseline HPV DNA positivity in the seropositive
women is consistent with some studies4’8’z and
higher than other studies.9,el This is not surprising;
in this study population where so many women had
abnormal cytology results, a high prevalence of
HPV DNA detected by a sensitive test such as
PCR should be expected. A unique aspect of this
study was the matching of the seropositive and se-
ronegative women for risk factors associated with
HPV DNA, including cytology, age, and number of
sexual partners. Given this matching, the similar
prevalences of HPV DNA detected at baseline in
these seropositive and seronegative women also is
not surprising. This finding is in contrast to other
studies where HPV detection was lower in HIV-
seronegative women.5,9,zl However, in previous
studies, the seropositive and seronegative women
were not matched.
This study also prospectively monitored these
HIV-seropositive and-seronegative women. De-
spite initial matching for cytologic reading, differ-
ences emerged upon follow up. The presence of
SIL on follow-up cytology was significantly more
likely among seropositive women. Conversely, se-
ronegative women had more negative cytologic
smears on follow up. This increase in progression
or persistence of abnormal Pap smears in seropos-
itive women monitored prospectively is consistent
with cross-sectional studies that have demonstrated
an increased prevalence of abnormal smears in se-
ropositive women and with one prospective study
that also demonstrated increased cytologic abnor-
malities in seropositive women.1 The increase in
cytologic abnormalities may be related to HIV-
mediated immune suppression.
After matching for cytologic abnormalities, no
significant differences in HPV DNA detection
were seen on initial examination. However, similar
to cytologic findings, differences were present on
follow-up evaluations. Any HPV DNA and mul-
tiple types of HPV DNA were detected more com-
monly at the seropositive women’s follow-up visits.
The fact that in the seropositive women, HPV
DNA was persistently detected is also consistent
with the findings of multiple cross-sectional studies
that have demonstrated increased HPV DNA in
seropositive women when compared with seroneg-
ative women.
In contrast to a prior colposcopic study that
found more extensive and multifocal disease in
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HIV-seropositive women,
8 the colposcopically de-
termined extent of lesion was not different be-
tween the HIV-seropositive and-seronegative
women in this study, where the seropositive and
seronegative groups were matched for Pap read-
ings. However, a trend toward increased number of
lesions was seen in the seropositive women. Both
groups had a relatively large amount of the cervix
involved in the lesion(s) (mean 4.7/18 sections or
25%). This may be because the group with LGSIL
initially underwent monitoring rather than early bi-
opsy and treatment.
Studies comparing detailed colposcopic descrip-
tions of cervical lesions between seropositive and
seronegative women have not been reported. The
standardized physical examination form recorded
for each patient visit in this study allowed such a
comparison, and differences in lesion characteris-
tics between the seropositive and seronegative
women were evident. Cervical lesions with sharp
borders, thick white color, and mosaicism are con-
cerning,zz These lesion characteristics were seen
more commonly in the seropositive women despite
initial matching for cytology and are consistent
with a greater prevalence of abnormal cytology in
the seropositive women. Further prospective stud-
ies comparing biopsy correlation with lesion ap-
pearance between seropositive and seronegative
women may be helpful to guide the clinical deci-
sions regarding appropriate biopsy frequency and
timing of treatment in seropositive women.
This study is small, and a high prevalence of
cervical and vaginal infections other than HPV was
not seen in either group. Although other cervical
infections have been suggested as cofactors for ac-
tivation of latent HPV in the cervix,z3 larger trials
where multivariate analyses are possible would be
needed to test for potential independent cofactors
in HPV DNA expression.
Prospective studies have demonstrated in-
creased cytologic abnormalities1 and increased
HPV DNA prevalencez4 in seropositive women.
This study matched subjects for HPV DNA risks
factors and also demonstrated increased cytologic
abnormalities and HPV DNA detection in seropos-
itive women evaluated prospectively. Additionally,
this study demonstrated that colposcopic appear-
ance of cervical lesions is more concerning in sero-
positive women, consistent with cytologic findings.
In women, HIV is an independent risk factor for
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SIL.1 HIV has also been associated with anal SIL
in men independent of HPV. zs Clearly, HIV-
seropositive women are at increased risk for SIL
development, persistence, and recurrence. The
reasons for this SIL persistence undoubtedly in-
volve HPV DNA expression, the degree of immu-
nosuppression, and other potential cofactors. The
exact clinical utility of HPV DNA detection in
monitoring seropositive women who are at in-
creased risk for SIL development and persistence
requires further study.
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